First in Human Results Presented at EuroPCR with Simultaneous Publication in EuroIntervention
Key Highlights:
1. The DurAVR™ Transcatheter Heart Valve (THV) First-in-Human Study demonstrated promising haemodynamic performance sustained to 1 year and restoration of nearnormal blood flow dynamics.
2. DurAVR™ THV demonstrated an outstanding safety profile: No mortality (all causes), no disabling stroke, no life-threatening bleeding, and no myocardial infarction were reported during any follow-up visits.
3. These encouraging preliminary First-in-Human study results will be further validated in an FDA-approved Early Feasibility Study (EFS) commencing soon
...nice confirmation for team AVR...
- Forums
- ASX - By Stock
- AVR
- Ann: FIH Results Presented at EuroPCR & Simultaneous Publication
Ann: FIH Results Presented at EuroPCR & Simultaneous Publication, page-2
-
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$18.32 |
Change
0.010(0.05%) |
Mkt cap ! $352.1M |
Open | High | Low | Value | Volume |
$18.30 | $19.00 | $18.00 | $350.4K | 19.10K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 474 | $18.09 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.33 | 60 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 474 | 18.090 |
1 | 50 | 18.080 |
1 | 160 | 18.070 |
1 | 200 | 18.050 |
1 | 1000 | 18.000 |
Price($) | Vol. | No. |
---|---|---|
18.330 | 60 | 1 |
18.380 | 71 | 1 |
18.470 | 276 | 1 |
18.480 | 31 | 1 |
18.500 | 1000 | 1 |
Last trade - 13.11pm 01/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online